Kinase News and Research

RSS

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

The effectiveness of sunitinib for the treatment of renal cell carcinoma could be enhanced with the addition of a cyclooxygenase-2 inhibitor, study findings show.

20 Feb 2013

Targeting p38alpha MAPK isoform can help treat CNS inflammatory diseases

A study by a leading Alzheimer's researcher at the University of Kentucky provides new evidence that will help researchers home in on the molecular mechanisms involved in inflammation of the central nervous system (CNS) and aid drug-development strategies for treating inflammatory neurological diseases.

20 Feb 2013

Study describes pharmacological action of TZDs directly on pancreas

A scientific study published on the journal Diabetes, edited by the American Diabetes Association, describes for the first time the pharmacological action of thiazolidinediones (TZDs) —anti-diabetic drugs— directly on pancreas, the organ which produces insulin.

18 Feb 2013

Oxidized CaMKII may increase risk of death in diabetics following heart attack

Having diabetes doubles a person's risk of dying after a heart attack, but the reason for the increased risk is not clear. A new University of Iowa study suggests the link may lie in the over-activation of an important heart enzyme, which leads to death of pacemaker cells in the heart, abnormal heart rhythm, and increased risk of sudden death in diabetic mice following a heart attack.

18 Feb 2013

Prions may be crucial in brain development during childhood

A molecule that is not only dangerous, but can help the brain grow. A few years ago it was found that certain proteins, the prions, when defective are dangerous, as they are involved in neurodegenerative syndromes such as the Creutzfeldt-Jakob and the Alzheimer diseases.

16 Feb 2013

IKBKE gene plays a key role in tobacco-induced lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

16 Feb 2013

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

The drug bevacizumab, also known by the trade name Avastin, shrinks tumors briefly in patients with an aggressive brain cancer known as glioblastoma multiforme, but then they often grow again and spread throughout the brain for reasons no one previously has understood. Now, Mayo Clinic researchers have found out why this happens.

15 Feb 2013

Combination of Methotrexat and Tofacitinib shows promise against rheumatoid arthritis

Together with colleagues from the international rheumatic diseases research community, scientists of the Charité - Universitätsmedizin Berlin have presented a new therapy approach for the treatment of rheumatoid arthritis (RA), a chronic form of joint inflammation.

14 Feb 2013

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Kaposi's sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV) hide within the worldwide human population. While dormant in the vast majority of those infected, these active herpesviruses can develop into several forms of cancer.

14 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Berkeley Lab researchers resolve EGFR activation mystery

Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have provided important new details into the activation of the epidermal growth factor receptor (EGFR), a cell surface protein that has been strongly linked to a large number of cancers and is a major target of cancer therapies.

12 Feb 2013

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Using two different compounds they developed, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been able to show in animal models that inhibiting a specific enzyme protects heart cells and surrounding tissue against serious damage from heart attacks.

10 Feb 2013

Glimmer of hope for imatinib-resistant GIST

The monoclonal antibody SR1 can significantly inhibit gastrointestinal stromal tumor cell growth, report researchers in the Proceedings of the National Academy of Sciences.

7 Feb 2013

Researchers assess complete landscape of kinome expression in cancer

When it comes to gene sequencing and personalized medicine for cancer, spotting an aberrant kinase is a home run. The proteins are relatively easy to target with drugs and plenty of kinase inhibitors already exist.

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, announced the initiation of a phase 2 study of dalantercept, a novel angiogenesis inhibitor that targets the activin receptor-like kinase 1 (ALK1) pathway.

5 Feb 2013

Previously poorly investigated signalling pathway crucial for proliferation of prostate cancer cells

A previously poorly investigated signalling pathway is crucial for the growth and proliferation of prostate cancer cells. An international research team discovered this when studying the enzyme "soluble adenylyl cyclase" that produces the second messenger molecule cAMP.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Oral toxicity is frequent limitation of mTOR therapy

Oral mucositis is a frequent complication in patients taking mTOR inhibitors and a major reason for dose reductions and discontinuations in clinical trials, according to a review of this class of cancer drugs.

4 Feb 2013

Study investigates R1441G mutation of Parkinson's disease

A team from the UPV/EHU-University of the Basque Country came across a mutation of the LRRK2 gene in 2004, which is particularly prevalent among the population of Gipuzkoa. It is the R1441G mutation and is known as the Basque mutation.

1 Feb 2013

Kinase News and Research

COX-2 inhibitor extends sunitinib activity in renal cell carcinoma

Targeting p38alpha MAPK isoform can help treat CNS inflammatory diseases

Study describes pharmacological action of TZDs directly on pancreas

Oxidized CaMKII may increase risk of death in diabetics following heart attack

Prions may be crucial in brain development during childhood

IKBKE gene plays a key role in tobacco-induced lung cancer

Pairing Avastin with dasatinib can stop lethal spread of glioblastoma multiforme

Combination of Methotrexat and Tofacitinib shows promise against rheumatoid arthritis

Tousled-like kinases play a key role in suppression and activation of herpesviruses

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Berkeley Lab researchers resolve EGFR activation mystery

Inhibiting JNK enzyme protects against ischemic/reperfusion injury

Glimmer of hope for imatinib-resistant GIST

Researchers assess complete landscape of kinome expression in cancer

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Acceleron commences dalantercept phase 2 study in metastatic renal cell carcinoma

Previously poorly investigated signalling pathway crucial for proliferation of prostate cancer cells

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Oral toxicity is frequent limitation of mTOR therapy

Study investigates R1441G mutation of Parkinson's disease

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News